Relmada Therapeutics CMO Cedric O'Gorman departs; separation agreement includes $414,500 payment

RELMADA THERAPEUTICS, INC.

Dr. Cedric O'Gorman's service as Chief Medical Officer ended January 3, 2024, by mutual agreement.
Separation agreement provides $414,500 payment and six months of COBRA premium coverage.
O'Gorman may exercise vested stock options under the 2021 Equity Incentive Plan until March 3, 2024, via cashless exercise.
Agreement includes confidentiality, release, and non-disparagement provisions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Cedric O'Gorman

Chief Medical Officer

RLMD · RELMADA THERAPEUTICS, INC.

Effective: 2024-01-03
Filed: January 11, 2024, 6:59 PM ET

On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cedric O'Gorman departed as Chief Medical Officer at RELMADA THERAPEUTICS, INC..

Action: concluded his service
Role: Chief Medical Officer

Exact text from the filing

On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.

View on SEC.gov

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-003000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.